CDK4/6 INHIBITOR

Clinical trials for CDK4/6 INHIBITOR explained in plain language.

Never miss a new study

Get alerted when new CDK4/6 INHIBITOR trials appear

Sign up with your email to follow new studies for CDK4/6 INHIBITOR, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet recruiting 1 Not yet finished but already full! 1

Brand or generic? new study tests palbociclib versions in advanced breast cancer

Disease control Ongoing

This study compares the effectiveness and safety of brand-name palbociclib (Ibrance) versus a local generic version in 100 Iraqi women with advanced HR+/HER2- breast cancer. Participants receive either the brand or generic drug alongside hormone therapy. The main goal is to see h…

Matched conditions: CDK4/6 INHIBITOR

Sponsor: Al-Mustansiriyah University • Aim: Disease control

Last updated May 01, 2026 16:01 UTC

CDK4/6 INHIBITOR

Get alerted when new CDK4/6 INHIBITOR trials appear

Brand or generic? new study tests palbociclib versions in advanced breast cancer